(Q50127167)

25 February 2018

title

Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials (English)

1 reference

25 February 2018

0 references

Zhu X

1

1 reference

25 February 2018

Zhang YP

series ordinal

2

1 reference

25 February 2018

Klopman G

series ordinal

3

1 reference

25 February 2018

Rosenkranz HS

series ordinal

4

1 reference

25 February 2018

language of work or name

English

0 references

publication date

1 March 1999

1 reference

25 February 2018

published in

Mutation Research

1 reference

25 February 2018

volume

425

1 reference

25 February 2018

issue

1

1 reference

25 February 2018

page(s)

153-167

1 reference

25 February 2018

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide suppresses T- and B-cell responses to myelin antigen in experimental allergic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide, a current teratogen in South America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide induced alteration in secondary structure of rat embryonic DNA in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Is thalidomide mutagenic?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide is not a mutagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Never-ending tales of the mode of the teratogenic action of thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide may be a mutagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide may be a mutagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The genetic toxicity of human carcinogens and its implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Detection of human carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide: lack of mutagenic activity across phyla and genetic endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Genetic toxicities of human teratogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

International Commission for Protection Against Environmental Mutagens and Carcinogens. Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTI-CASE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The carcinogenicity prediction and battery selection (CPBS) method: a Bayesian approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Prediction of the carcinogenicity of a second group of organic chemicals undergoing carcinogenicity testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Estimation of the optimal data base size for structure-activity analyses: the Salmonella mutagenicity data base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Prediction of Salmonella mutagenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The structural basis of the carcinogenic and mutagenic potentials of phytoalexins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Reproducibility of microbial mutagenicity assays: I. Tests with Salmonella typhimurium and Escherichia coli using a standardized protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Reproducibility of microbial mutagenicity assays: II. Testing of carcinogens and noncarcinogens in Salmonella typhimurium and Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Structural basis of carcinogenicity in rodents of genotoxicants and non-genotoxicants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Risk identification using structural concepts: the potential carcinogenicity of praziquantel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Identification of a 2-D geometric descriptor associated with non-genotoxic carcinogens and some estrogens and antiestrogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

A carcinogenic potency database of the standardized results of animal bioassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1982.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Second chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Third chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The fifth plot of the Carcinogenic Potency Database: results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The carcinogenicity of diethylstilbestrol: structural evidence for a non-genotoxic mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice: the carcinogenic potency database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Structural determinants associated with risk of human developmental toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

META. 1. A program for the evaluation of metabolic transformation of chemicals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

META. 2. A dictionary model of mammalian xenobiotic metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A coated plastic surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Studies on the potential for genotoxic carcinogenicity of fragrances and other chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The fate of[14C]thalidomide in the pregnant rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

The fate of the hydrolysis products of thalidomide in the pregnant rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Metabolic fate of thalidomide in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

Teratological tests of the hydrolysis products of thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

[The L-isomer as teratogenic principle of N-phthalyl-DL-glutamic acid]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

From mutagen hunter to genome defender, a change in paradigm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-5107%2899%2900035-4

10.1016/S0027-5107(99)00035-4

7 January 2021

Identifiers

DOI

1 reference

25 February 2018

1 reference

25 February 2018